Ranking Invest

ACLX - Arcellx, Inc.

Segmento: HealthcareArcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Análise Ranking Invest

Valuation estimado
-$ 29.30 Mi
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 416.91 Mi

Dívida Líquida

-$ 27.67 Mi

L4T

-$ 162.42 Mi

MM4T

-318.28%

Indicadores Básicos

ROE

-38.96%

Índices de Previsibilidade

Faturamento

0.75

Lucro

0.52

Margem

0.95

Índices de Tendência

Faturamento

6.96

Lucro

-1.26

Margem

-7.49

Índices de Endividamento

DIV/PAT

-0.07

DIV/L4T

0.17

Dívidas
Cotação
Gráfico Lucro/Faturamento X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.